Search
Carbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalSince 2002, FDA has favorably reviewed three GRAS notifications for carbon monoxide use in fresh meat packaging [L2537]. … The FDA classifies this drug as permitted as a food additive in the packaging and preparation of food products, while following the federal code of regulations [L2531].
Invert sugar
go.drugbank.com/drugs/DB09344Experimental[A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS).
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalPacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsPentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnIt is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395].
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.
Categories: Smoothened Receptor AntagonistsVadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]